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Cost Analysis
Direct medical costs were evaluated from the hospital provider's (HP) perspective. Unit costs for diagnostics, medication, hospitalization, and hospitaloutpatientcarewereprovidedbythecontrollingdepartmentof the university hospital for the year 2008. Because of the chronic, yet episodic and relapsing nature of ITP, costs were calculated as average costsperpatientafterevaluationoftotalITP-relatedcostsforeachpatientaccumulatedduringhisorherindividualobservationperiod.Costs were stratified according to the revised definitions of Rodeghiero et al. [3] ascostsfor'newlydiagnosedITP'definedbyanewdiagnosisofITP lessthan3monthsago,'persistentITP'withdiseasedurationfromfirst diagnosisofITPof≥3to<12months,and'chronicITP'withdiseasedurationof≥12months [3] .
Statistical Analysis
Data were analyzed with SAS software version 9.1 (SAS Institute Inc., Cary, NC, USA). Descriptive statistics were calculated by reporting frequency distributions of study parameters as well as means, standard deviations(SD),andmedians.
Results
Database screening provided 194 patients of whom 144 patientswerenoteligibleforthestudybecauseofotherreasons forthrombocytopeniaand50patientswithITPwereincluded for evaluation. The median age of eligible patients was 55.5yearsatthefirstITP-relatedvisittothehospital(interquartilerange34-71years)(table1),wherebyfemalepatients were on average younger than male patients (29 female patients,medianage43.0years,interquartilerange34-66years, not normally distributed versus 21 male patients, median age61years,interquartilerange45-71years,normallydistributed). In 45 patients (90%), the start of the observation
Introduction
Immune thrombocytopenia (ITP) is characterized by a reduced number of platelets in the circulating blood (platelet countlessthan100×10 9 /l) [1] [2] [3] .ThediagnosisofITPcanbe establishedonlyafterothercausesofthrombocytopenia,such as leukaemia, myelodysplasia, aplastic anaemia, infections including human immunodeficiency virus (HIV), hepatitis C or Helicobacter pylori, and drug-induced immune reactions have been ruled out [4] . The annual incidence of ITP in NorthernEuropeisestimatedtobe2.7casesper100,000and tends to increase with age [5] . In the age group between 30 and60years,apreponderanceofwomenisfound [4, 5] .
Historically, the pathogenesis of ITP has been attributed solely to platelet autoantibody production and subsequent plateletdestruction [6] .Recentfindingssupportinvolvement of impaired platelet production as an additional cause for thrombocytopenia. Suppression of megakaryopoiesis by autoantibodies and dysfunction in the regulation of thrombopoietin(TPO)synthesisgiverisetoimpairedthrombopoiesis [7] . The clinical course of ITP shows high variability in duration and severity, and response to most conventional therapeutic strategies remains largely unpredictable. Treatmentisclearlyindicatedinpatientswithplateletcountsbelow 30×10 9 /landpresenceofactivebleeding [4, 8, 9] .Corticosteroids are the standard initial treatment for newly diagnosed patients [1, 4] .Intravenousimmunoglobulin(IVIG)isalsoa recommended first-line treatment strategy with an expected shorter time to response and possible enhancement of response if given together with corticosteroids [1, 4] . SecondlinetreatmentoptionsforadultITPpatientsincludevarious immunosuppressants, splenectomy, and the TPO receptor agonists romiplostim and eltrombopag. TPO receptor agonistsstimulateplateletproductionandenablepatientstodiscontinueanoftenlong-termimmunosuppressivetherapy [1, 4, 10] .TherapeuticdecisionsforindividualITPpatients,particularlythosewithchronicITP,oftenhavetobemadeconsideringbleedinghistory,potentialrisksofdifferenttherapies,the patient'sage,pre-existingdiseases,andlifestyle [3, 4] .
Todate,noinformationisavailableontreatmentpatterns and costs for ITP patients in Germany. Therefore, we conducted a retrospective, single-centre, observational study to describe therapeutic characteristics of these patients in Germany.Alargereferralcentrewaschosentostudythecourse ofthediseaseanditsclinicalmanagement,aswellasresource consumptionandcostsinagroupofadultpatientswithITP.
Patients and Methods
Aretrospective,observational,single-centrestudyofITPwasconducted intheDepartmentofHaematology/OncologyattheUniversityHospital ofMunich,Germany.Inclusioncriteriaforeligiblepatientswereaminimumageof18years,firstdiagnosisofITPbetween1January2000and 31 December 2007, and either inpatient or outpatient treatment in the Bauer/Baumann/Berger/Ackermann/ Shlaen/Schopohl/Ostermann period with the first visit to the hospital was also the date of the first ITP diagnosis. The remaining 5 patients had a first diagnosis of ITP after 1 January 2000, but had been diagnosedelsewhere1,7,21,31,and35months,respectively, before their first visit to this hospital and therefore did not haveacompletedatasetforresourceconsumptionandcosts for the whole disease duration. At the time of the first visit to the hospital, 42 patients (84%) suffered from additional, not thrombocytopenia-related pre-existing diseases, mainly cardiovascular, endocrine, and genitourinary (38, 36, and 32%, respectively)(table1).Atotalof33patients(66%)presentedontheirfirstvisittothehospitalwithplateletcounts ≤10×10 9 /l,12patients(24%)withplateletcounts>10to≤30 ×10 9 /l,and5patients(10%)withplateletcounts>30to≤100 × 10 9 /l. At the end of the observation period, 32 patients (64%) had platelet counts > 100 × 10 9 /l, 15 patients (30%) had platelet counts of > 30 to ≤ 100 × 10 9 /l, and 3 patients hadplateletcountsofonly>10to≤30×10 9 /l(table1).The average length of the observation period per patient was 15±18months(mean±SD)(median5months,minimum0.2, maximum72).
Complications
In 43 patients (86%) with bleeding ( (table 1) . Atotalof20infectionswereobservedwithanaveragedura-tionof8.7±6.4days(mean±SD),16underimmunosuppres-sivetherapyand4woundinfectionsaftersplenectomy.3in-fections required hospitalization. 1 82-year-old patient with multiple (not ITP-related) pre-existing diseases, who was treated with steroids and IV IG, died early in the course of disease from sepsis as could be confirmed by post mortem examination. Table 2 contains data on resource consumption during the observationperiod.Atotalof45patientswerehospitalized, withameanof2admissionsperpersonandatotalof92ITP-related inpatient admissions. A first diagnosis of ITP was madeduring37oftheseinpatientadmissions(40%).For19 admissions to the hospital (21%), the ITP-related reasons werediverse,including4relapses,2rehabilitations,2adverse events, 1 plastic surgery of the skullcap after intracranial haemorrhage, complications after splenectomy, and infections. Overall, 955 outpatient visits were documented, 752 were to the hospital outpatient ward, and 203 were visits to office-based physicians. The most common reasons for ITPrelatedoutpatientvisitswerecheck-upsduringtherapy(50%) orroutinemonitoringofbloodcountbeforeoraftertherapy (33%).26patients(52%)weretestedforplateletantibodies, and50%ofthetests(17of34)werepositive(table2).
Resource Consumption

Duration of ITP
A total of 19 patients (38%) had a duration of ITP after diagnosis for less than 3 months and therefore had newly diagnosedITPbythereviseddefinitionsofRodeghieroetal. (13) 11 (22) Gastrointestinal (9) 8(16) Oralbleeding (8) 6(12) Haematuria (8) 5(10) Menorrhagia (4) 4(8) Intracranial (3) 3(6) Surgeryassociated (4) 3(6) Muscular (1) 1(2) Infections(n)
Totalpatients (20) 12 (24) Respiratory (10) 5(10) Woundinfection (4) 3(6) Dermatologic (1) 1(2) Cardiovascular (1) 1(2) Unknown (4) 2 (4) a Lowestplateletcountmeasuredatthestartoftheobservationperiod. Ofthe5patientswithplateletcounts>30to≤100,1hadalready receivedsteroids,3stayedwithouttreatment,and1hadaplatelet countof33×10 9 /l. sodes with a mean duration of 362 ± 289 days (mean ± SD; median277,range50-1,049).1patienthadreceivedcorticos-teroidtherapybeforethefirstvisittothishospital. Atotalof12patients(24%)underwentsplenectomy,and in1patient2surgerieswereperformedbecauseofaccessory splenictissue(table3).ThemeantimeintervalbetweenITP diagnosis and splenectomy was 18.7 ± 20.5 months (mean ± SD; median 10.8, range 1-64; data not shown), whereby 6patientsunderwentsplenectomyearlyinthecourseofdis-ease between > 1 month and ≤ 1 year, and 6 patients late between > 1 year until up to 5.4 years after diagnosis. 5 patients (42% of all splenectomised patients) received further drugtreatmentsaftersplenectomy.
A total of 17 patients (34%) received transfusions of packed red cells, platelets, or fresh frozen plasma (table 3) . 3 of these patients received platelets in preparation for splenectomy.
Costs
The average total direct medical cost per patient associated with ITP during the individual observation period was €17,091±€18,859(n=50;mean±SD)fromtheHPperspective (table 4) , with over 90% of those costs (€15,710 ± €18,068;n=50)attributabletoinpatientcare.Averagecosts foroutpatientcarecomprised€1,381±€1,988(n=50).The average cost per inpatient admission in our sample (n = 92) was€8,519fromtheHPperspective.Intotal,themeandirect cost per patient (n = 45) for an inpatient stay amounted to €17,455,andthemeancostperpatient(n=39)foranoutpa- (1±0) 4 (8) a Mean±standarddeviation. b Includinghospitaloutpatientvisitsandvisitstooffice-basedphysicians. (9) 1 (2) a Plateletsloadedwiththevincaalkaloidvincristine [11] . IVIG=Intravenousimmunoglobulin;SD=standarddeviation.
Bauer/Baumann/Berger/Ackermann/ Shlaen/Schopohl/Ostermann amounted to €2,877 ± €537 (mean ± SD; median €2,927, range €2,190-3,465). For the 17 patients with newly diagnosed ITP, average costs were €12,749 ± €11,663 (mean ±SD;median€8,446,range€2,243-45,605),andaveragefollow-upwas0.88months±0.65months(mean±SD;median 0.62months,range0.20-2.26months).Forthe6patientswith persistentITP,averagecostsamountedto€14,899±€8,832 (mean ± SD; median €13,537, range €1,188-26,418), and average follow-up was 7.91 months ± 2.97 months (mean ± SD; median 7.85 months, range 4.33-11.25 months). For the 13 patients with chronic ITP, average costs were €29,868 ± €29,397 (mean ± SD; median €17,235, range €2,480-105,701), and average follow-up was 33.47 months ± 16.79 months(mean±SD;median35.44months,range13.54-72.30 months). tient visit to €1,771 (table 4) . The highest mean costs arose fromhospitalcareincludinglaboratorytestswith€9,658and drugtherapywith€5,847forinpatientadmissions,andfrom hospitaloutpatientcareandlaboratorytestswith€1,543for outpatientvisits(table4). Average costs for the 12 splenectomised patients were €39,490 ± €22,020 (mean ± SD; median €32,649, range €17,235-105,235) compared to average costs of €10,018 ± €9,850fornon-splenectomisedpatients(mean±SD;median €7,769,range€1,188-56,904).
StratificationofthetotaldirectmedicalcostsfromtheHP perspective according to duration and treatment of ITP is showninfigure1.Onlypatientswithacompletedataset,i.e. firstdiagnosisofITPinthishospital,couldbeincluded.Average costs for the 4 patients without ITP-related treatment [12] . The meanlengthofhospitalstayinoursmallsamplefromalarge referralcentrewas12days,whichisalmosttwiceasmuchas theaveragelengthofstayofITPpatientsintheUSdatabase studywith6.4days [12] .Aconsiderableproportionofthepatients in our study presented with severe ITP, namely clinically relevant bleeding [3] . Choosing a university hospital couldthereforebealimitationofthestudyduetopre-selectionofmoresevereITPcases.AlthoughthedifferenthealthcaresystemsoftheUSandGermanyaswellasthedifferent studydesignsargueagainstadirectcomparison,bothstudies show that hospitalisation for ITP is economically and clinically relevant. Overall consumption of healthcare resources mightstillhavebeenunderestimatedinourstudyforthefollowingreasons:Documentationofpatients'office-basedvisits wasnotcomprehensive.Therewasnodefinedminimumobservation time after the first visit to the hospital because it wasaretrospectivestudy.Morethanhalfofthepatientswere stillontherapyattheendofthestudy,andin5patientsthe firstvisittothehospitalwasconsiderablylaterthanthedate ofthefirstdiagnosisofITP.
The baseline demographics of our sample appear to be consistentwiththeITPpatientpopulationsinotherpublished studies [13, 15, 16] . However, a single-centre study does not allow extrapolation for the general situation regarding costs andresourceconsumptionofITPpatientsinGermany.There are additional limitations of our study partly caused by the heterogeneityofthisrarediseaseandbythestudydesign.The studywasconductedretrospectively,andtestsforHIV,hepatitis C or H. pylori, and serologies ruling out other autoimmunediseaseswerenotpartofroutineclinicaltestinginall patients.Thedesignwassingle-centreoveralongtimeperiod in the past yielding only a small and heterogenous group of patientswithalargeproportionofnewlydiagnosedITPpatients. And finally, a standardized observation period and detaileddatafromoffice-basedphysicianswerenotavailable.
Inconclusion,wehavedescribedforthefirsttimecurrent healthcare provision in routine clinical practice including treatment,resourceconsumption,andcostsforagroupofITP patientsinGermany.Differenttreatmentoptionsforthisrare disease with their accompanying risks, episodes of bleeding andinfection,andincreasingageofthepatientsgeneratehigh costs. Further investigations are necessary to obtain a more complete picture of the total burden of ITP including a broader spectrum of hospitals and private practices, the patients' view of the disease affecting quality of life, patients' preferences,andlastbutnotleastnewandeffectivetreatment Discussion Bleeding events and sepsis are the 2 major complications in ITPleadingtoanincreasedmortalityrate [12, 13] .Oursmall group of 50 ITP patients comprised 3 patients with intracranial haemorrhage and 1 patient who died of sepsis. Our findingsunderscoretheneedtochoosetherapytoavoidfatal haemorrhage [1, 4, 9] .Inaddition,theriskofsevereinfection hastobeconsideredespeciallyinelderlypatientswithmultiplepre-existingdiseases.2majortreatmentoptionsareasso-ciatedwithanincreasedriskofinfection,immunosuppressive drug treatment and splenectomy. Standard initial treatment fornewlydiagnosedITPisstillcorticosteroids [1, 4] .Inarecentdatabasestudyontheburdenofillnessofadultchronic ITPintheUS,96.5%ofthepatientswhoreceivedpharmaco-logic therapy during the first 1-1.5 years of follow-up were treatedwithoralcorticosteroids [14] .
Arelativelylowrateof24%forsplenectomy(12patients) wasobserved.1patientunderwent2surgicalproceduresdue to the presence of accessory splenic tissue as found in up to 12% of non-responding patients [9] . Splenectomy rates reported in other studies vary considerably (e.g., 12% [15] or 24% [16] or58% [13] ).Availablestudydataonsplenectomy showaconsistentresponserateofover60%,anditistherefore an established treatment option with the goal of longterm remission [3, [17] [18] [19] . However, for the single ITP patient, outcome of splenectomy cannot be predicted [17] . Therefore, several authors propose a delay of several years beforeproceedingtosplenectomy [16, 20, 21] .Wehavenoinformation on whether additional reasons like refusal of the patienttoundergosurgeryorpre-existingdiseasesprecluded splenectomyasatreatmentoptioninsomeofthepatientsin our study. In the mean time, new treatment options have emerged with the TPO receptor agonists romiplostim and eltrombopag.TPOreceptoragonistsarehighlyeffectiveand indicatedforthetreatmentofthrombocytopeniainadultpatientswithchronicITPwhohavehadaninsufficientresponse tocorticosteroids,immunoglobulins,orsplenectomy [1, 4, 10] .
A considerable amount of ITP-related healthcare resourceswasusedbythepatientsinourstudy,withthemain costdriversbeinginpatienthospitalstays.Patientsandtheir observationperiodswereheterogeneous,resultinginabroad variation of the total costs per patient (€1,188-105,701). Therefore, patients with treatment were classified. Newly diagnosed ITP patients used on average €12,749 ± €11,663 and these costs more than doubled for chronic ITP patients withanamountof€29,868±€29,397.Thecalculatedaverage yearlycostsforachronicITPpatientinourstudyamountto €10,667, which is in the order of the mean cost per patient and year -1 of €7,293 evaluated for 57 patients with chronic ITPinarecentretrospectiveFrenchstudy [22] .Averagecosts perITP-relatedhospitalisation(n=92)amountedto€8,519 from the HP perspective, which is considerably higher than
